Senators Press HHS on Prediction Markets for Drug Trials
The senators asked HHS for internal communications and risk analyses as Kalshi and Polymarket face scrutiny over contracts tied to drug trials and FDA approvals.
7 Articles
7 Articles
Prediction markets tied to clinical trials and drug approvals draw lawmakers’ ire
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services headquarters in Washington, April 22, 2025.Nathan Posner | Anadolu | Getty ImagesPrediction market event contracts on both clinical drug trials and Food and Drug Administration regulatory approvals are drawing attention from two Democratic senators,…
Democratic senators ask HHS for explanations on forecast markets linked to FDA clinical trials and approvals, according to CNBC
Two Democratic senators asked the Department of Health to examine the risks of prediction contracts on clinical trials and drug approvals, with particular concern for patients and the possible use of non-public information.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
